Baas H, Schneider E, Fischer P A, Japp G
J Neural Transm. 1985;64(1):45-54. doi: 10.1007/BF01259344.
24 levodopa pretreated patients with advanced parkinsonism were split into two equal groups receiving mesulergine or bromocriptine respectively as an adjuvant therapy. The trial was carried out under double blind conditions the first three months and then continued as an open trial for one year. Clinical benefit was similar in both groups with minor differences in regard to single symptoms. While bromocriptine showed a beginning decline in efficacy after one year, mesulergine showed no decline. The mean mesulergine-dose, necessary to achieve good clinical improvement, was about half of bromocriptine. Side-effects were similar, except orthostatic hypotension requiring vasopressor medication, which was less frequent in mesulergine treated patients. This advantage of mesulergine might be explained by its special pharmacological pattern with biphasic action on dopaminergic receptors.
24例接受左旋多巴预处理的晚期帕金森病患者被分为两组，每组人数相等，分别接受美舒麦角或溴隐亭作为辅助治疗。试验前三个月在双盲条件下进行，然后作为开放试验持续一年。两组的临床疗效相似，在单一症状方面存在细微差异。虽然溴隐亭在一年后显示出疗效开始下降，但美舒麦角没有下降。实现良好临床改善所需的美舒麦角平均剂量约为溴隐亭的一半。副作用相似，但需要血管升压药物治疗的体位性低血压在接受美舒麦角治疗的患者中较少见。美舒麦角的这一优势可能与其对多巴胺能受体具有双相作用的特殊药理模式有关。
